Effectiveness of ustekinumab for moderate-to-severe hidradenitis suppurativa: a case series

J Dermatolog Treat. 2022 Mar;33(2):1159-1162. doi: 10.1080/09546634.2020.1776208. Epub 2020 Jun 11.
No abstract available

Publication types

  • Letter

MeSH terms

  • Dermatologic Agents* / therapeutic use
  • Hidradenitis Suppurativa* / drug therapy
  • Humans
  • Severity of Illness Index
  • Ustekinumab / therapeutic use

Substances

  • Dermatologic Agents
  • Ustekinumab